Share Email Print
cover

Proceedings Paper

Nanoelectroablation for human carcinoma therapy
Author(s): Richard Nuccitelli; Mark Kreis; Brian Athos; Ryan Wood; Joanne Huynh; Kaying Lui; Pamela Nuccitelli; Ervin Epstein
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The use of nanosecond pulsed electric fields to ablate tumors (nanoelectroablation) is now well established in the murine xenograft model system. In order bring this therapy into the clinic for the treatment of human tumors we are developing both a pulse generator as well as delivery electrodes to target the tumors to be treated. We will describe the PulseCure® Model MBR-1 100 ns pulse generator and the first human clinical trial data using nanoelectroablation to scarlessly ablate basal cell carcinomas.

Paper Details

Date Published: 23 February 2013
PDF: 6 pages
Proc. SPIE 8585, Terahertz and Ultrashort Electromagnetic Pulses for Biomedical Applications, 85850G (23 February 2013); doi: 10.1117/12.2002538
Show Author Affiliations
Richard Nuccitelli, BioElectroMed Corp. (United States)
Mark Kreis, BioElectroMed Corp. (United States)
Brian Athos, BioElectroMed Corp. (United States)
Ryan Wood, BioElectroMed Corp. (United States)
Joanne Huynh, BioElectroMed Corp. (United States)
Kaying Lui, BioElectroMed Corp. (United States)
Pamela Nuccitelli, BioElectroMed Corp. (United States)
Ervin Epstein, Children's Hospital Oakland Research Institute (United States)


Published in SPIE Proceedings Vol. 8585:
Terahertz and Ultrashort Electromagnetic Pulses for Biomedical Applications
Gerald J. Wilmink; Bennett L. Ibey, Editor(s)

© SPIE. Terms of Use
Back to Top